document.write("<style type=text/css>A.sg-embeddednews-link {color:#333333;text-decoration:underline;}A.sg-embeddednews-link:Active {color:#333333;text-decoration:underline;}A.sg-embeddednews-link:Visited {color:#333333;}A.sg-embeddednews-link:Hover {color:#330161;text-decoration:none;}td.sg-embeddednews-title {}.sg-embeddednews-date {color : #000000;font-weight: bold;	}td.sg-embeddednews-content {font-size: 12px; font-family : Arial;	}</style>"); document.writeln("<table width=100% border=0 cellpadding=1 cellspacing=0 ><tr valign=top><td class=sg-embeddednews-content ><span class='sg-embeddednews-date'>July 29, 2010</span><br><a class='sg-embeddednews-link' href=http://media.integratir.com/T.ONC/PressReleases/ONC_Q2_2010_29-07-10.pdf target=newswindow>Oncolytics Biotech(R)Inc. Announces Second Quarter 2010 Results</a><br><br><span class='sg-embeddednews-date'>July 19, 2010</span><br><a class='sg-embeddednews-link' href=http://www.integratir.com/newsrelease.asp?news=2131023544&ticker=T.ONC&lang=EN&ny=on target=_self>Oncolytics Biotech® Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN® in Head and Neck Cancers</a><br><br><span class='sg-embeddednews-date'>June 17, 2010</span><br><a class='sg-embeddednews-link' href=http://www.integratir.com/newsrelease.asp?news=2131023467&ticker=T.ONC&lang=EN&ny=on target=_self>Oncolytics Biotech® Inc. Announces Issuance of 35th U.S. Patent</a><br><img src=http://www.integratir.com/images/pixel.gif width=1 height=8><br></td></tr></table>");